The multi-epitope approach for immunotherapy for cancer: Identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors

Human Immunology

Volumn 59, Issue 1, 1998, Pages 1-14

  Kawashima, Ichiro ^a,b   Hudson, Stephen J ^a   Tsai, Van ^a   Southwood, Scott ^a   Takesako, Kazutoh ^b   Appella, Ettore ^c   Sette, Alessandro ^a   Celis, Esteban ^a  

^a CYTEL CORPORATION   (United States)

^b TAKARA SHUZO CO LTD   (Japan)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; EPITOPE; HLA A2 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EPITHELIUM TUMOR; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOREACTIVITY; PRIORITY JOURNAL; SOLID TUMOR;

ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; BREAST NEOPLASMS; COLONIC NEOPLASMS; CYTOTOXICITY TESTS, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; GASTROINTESTINAL NEOPLASMS; HLA-A2 ANTIGEN; HUMANS; IMMUNOCHEMISTRY; IMMUNOTHERAPY, ADOPTIVE; LUNG NEOPLASMS; POLYMERASE CHAIN REACTION;

EID: 0031937298     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0198-8859(97)00255-3     Document Type: Article

References (64)

1. Nabholz M, MacDonald HR. Cytolytic T lymphocytes. Annu Rev Immunol. 1:1983;273.
2. Lanzavecchia A. Identifying strategies for immune intervention. Science. 260:1993;937.
3. Berke G. The binding and lysis of target cells by cytotoxic T lymphocytes Molecular and cellular aspects . Annu Rev Immunol. 12:1994;735.
4. Townsend A, Bodmer H. Antigen recognition by class I-restricted T lymphocytes. Annu Rev Immunol. 7:1989;601.
5. Rammensee HG, Falk K, Rotzschke O. Peptides naturally presented by MHC class I molecules. Annu Rev Immunol. 11:1993;213.
6. York IA, Rock KL. Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol. 14:1996;369.
7. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol. 12:1994;337.
8. Urban JL, Schreiber H. Tumor antigens. Annu Rev Immunol. 10:1992;617.
9. Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today. 18:1997;175.
10. Fisk B, Blevins TL, Wharton JT, Ioannides CG. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med. 181:1995;2109.
11. Disis ML, Smith JW, Murphy AE, Chen W, Cheever MA. In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein. Cancer Res. 54:1994;1071.
12. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA. 92:1995;432.
13. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst. 87:1995;982.
14. Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CL Jr. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science. 264:1994;716.
15. Skipper JCA, Hendrickson RC, Gulden PH, Brichard V, Pel AV, Chen Y, Shabanowitz J, Wolfel T Jr, CLS Boon T, Hunt DF, Engelhard VH. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med. 183:1996;527.
16. Celis E, Sette A, Grey HM. Epitope selection and development of peptide based vaccines to treat cancer. Sem Cancer Biol. 6:1995;329.
17. Appella E, Loftus DJ, Sakaguchi K, Sette A, Celis E. Synthetic antigenic peptides as a new strategy for immunotherapy of cancer. Biomed Pep, Proteins Nucleic Acids. 1:1995;177.
18. Celis E, Fikes J, Wentworth P, Sidney J, Southwood S, Maewal A, Del Guercio MF, Sette A, Livingston B. Identification of potential CTL epitopes of tumor-associated antigen MAGE-1 for five common HLA-A alleles. Molec Immunol. 31:1994;1423.
19. Tsai V, Southwood S, Sidney J, Sakaguchi K, Kawakami Y, Appella E, Sette A, Celis E. Identification of subdominant CTL epitopes of the gp100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J Immunol. 158:1997;1796.
20. Celis E, Tsai V, Crimi C, DeMars R, Wentworth PA, Chesnut RW, Grey HM, Sette A, Serra HM. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci USA. 91:1994;2105.
21. Weynants P, Lethe B, Brasseur F, Marchand M, Boon T. Expression of MAGE genes by non-small-cell lung carcinomas. Int J Cancer. 56:1994;826.
22. De Plaen E, Arden K, Traversari C, Gaforio JJ, Szikora J-P, De Smet C, Brasseur F, van der Bruggen P, Lethe B, Lurquin C, Brasseur R, Chomez P, De Backer O, Cavenee W, Boon T. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenet. 40:1994;360.
23. Vincent RG, Chu TM. Carcinoembryonic antigen in patients with carcinoma of the lung. J Thorac Cardiovasc Surg. 66:1978;320.
24. Shively J, Beatty J. CEA-related antigens Molecular biological and clinical significance . CRC Crit Rev Oncol Hematol. 2:1985;355.
25. Thompson J, Grunert F, Zimmerman W. CEA gene family Molecular biology and clinical perspectives . J Clin Lab Anal. 5:1991;344.
26. Sikorska H, Shuster J, Gold P. Clinical applications of carcinoembryonic antigen. Cancer Detect Prev. 12:1988;321.
27. Muraro R, Wunderlich D, Thor A. Definition by monoclonal antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human colon carcinomas versus normal adult tissues. Cancer Res. 45:1985;5769.
28. Steward AM, Nixon D, Zamcheck N, Aisenberg A. Carcinoembryonic antigen in breast cancer patients Serum levels and disease progress . Cancer. 33:1974;1246.
29. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 244:1989;707.
30. Yokota J, Yamamoto T, Toyoshima K, Terada M, Sugimura T, Battifora H, J CM. Amplification of the c-erbB-2 oncogene in human adenocarcinomas in vivo. Lancet. 1:1986;765.
31. Ruppert J, Sidney J, Celis E, Kubo RT, Grey HM, Sette A. Prominent role of secondary anchor residues in peptide binding to HLA-A2 1 molecules . Cell. 74:1993;929.
32. Sette A, Sidney J, del Guercio MF, Southwood S, Ruppert J, Dahlberg C, Grey HM, Kubo RT. Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. Molec Immunol. 31:1994;813.
33. del Guercio MF, Sidney J, Hermanson G, Perez C, Grey HM, Kubo RT, Sette A. Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype. J Immunol. 154:1995;685.
34. De Smet C, Lurquin C, van der Bruggen P, De Plaen E, Brasseur F, Boon T. Sequence and expression pattern of the human MAGE2 gene. Immunogenet. 39:1994;121.
35. Gaugler B, Van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, De Plaen E, Lethe B, Brasseur F, Boon T. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med. 179:1994;921.
36. Zakut R, Topalian SL, Kawakami Y, Mancini M, Eliyahu S, Rosenberg SA. Differential expression of MAGE-1, -2, and -3 messenger RNA in transformed and normal human cell lines. Cancer Res. 53:1993;5.
37. Kocher T, Schultz-Thater E, Gudat F, Schaefer C, Casorati G, Juretic A, Willimann T, Harder F, Heberer M, Spagnoli GC. Identification and intracellular location of MAGE-3 gene product. Cancer Res. 55:1995;2236.
38. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacker B, Konwalkinka G, Fritsch PO, Steinman RM, Schuler G. Proliferating dendritic cell progenitors in human blood. J Exp Med. 180:1994;83.
39. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α J Exp Med. 179:1994;1109.
40. Russo V, Traversari C, Verrecchia A, Mottolese M, Natali PG, Bordignon C. Expression of the MAGE gene family in primary and metastatic human breast cancer Implications for tumor antigen-specific immunotherapy . Int J Cancer. 64:1995;216.
41. van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boel P, De Smet C, Traversari C, Townsend A, Boon T. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol. 24:1994;3038.
42. Rammensee H-G, Friede T, Stevanovic S. MHC ligands and peptide motifs first listing . Immunogenet. 41:1995;178.
43. Sette A, Vitiello A, Reherman B, Fowler P, Nayersina R, Kast WM, Melief CJ, Oseroff C, Yuan L, Ruppert J, Sidney J, del Guercio M-F, Southwood S, Kubo RT, Chesnut RW, Grey HM, Chisari FV. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol. 153:1994;5586.
44. Parkhurst MR, Salgaller ML, Southwood S, Robbins PF, Sette A, Rosenberg SA, Kawakami Y. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol. 157:1996;2539.
45. Topalian SL, Gonzales MI, Parhurst M, Li YF, Southwood S, Sette A, Rosenberg SA, Robbins PF. Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med. 183:1996;1965.
46. Sidney J, Grey HM, Kubo RT, Sette A. Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs. Immunol Today. 17:1996;261.
47. Lustgarten J, Theobald M, Labadie C, LaFace D, Peterson P, Disis ML, Cheever MA, Sherman LA. Identification of Her-2/Neu CTL epitopes using double trangenic mice expressing HLA-A2 1 and human CD8 . Human Immunol. 52:1997;109.
48. Traversari C, van der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van Pel A, De Plaen E, Amar-Costesec A, Boon T. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med. 176:1992;1453.
49. van der Bruggen P, Szikora JP, Boel P, Wildmann C, Somville M, Sensi M, Boon T. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601. Eur J Immunol. 24:1994;2134.
50. Fleischhauer K, Fruci D, Van Endert P, Herman J, Tanzarella S, Wallny HJ, Coulie P, Bordignon C, Traversari C. Characterization of antigenic peptides presented by HLA-B44 molecules on tumor cells expressing the gene MAGE-3. Int J Cancer. 68:1996;622.
51. van der Burg SH, W. VMJ Offringa R, Melief CJM. Do epitopes derived from autoantigens display low affinity for MHC class I? Immunol Today. 18:1997;97.
52. Fairchild PJ, Wraith DC. Lowering the tone mechanisms of immunofominance among epitopes with low affinity for MHC . Immunol Today. 12:1996;80.
53. Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating lymphocytes associated with in vivo tumor regression. J Immunol. 154:1995;3961.
54. Theobald M, Biggs J, Hernandez J, Lustgarten J, Labadie C, Sherman LA. Tolerance to p53 by A2 1-restricted cytotoxic T lymphocytes . J Exp Med. 185:1997;833.
55. Röpke M, Hald J, Guldberg P, Zeuthen J, Norgaard L, Fugger L, Svejgaard A, Van der Burg S, Nijman HW, Melief CJ, Claesson MH. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc Natl Acad Sci USA. 93:1996;14704.
56. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 253:1991;49.
57. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature. 351:1991;453.
58. Fleischhauer K, Tanzarella S, Wallny H-J, Bordignon C, Traversari C. Multiple HLA-A alleles can present an immunodominant peptide of the human melanoma antigen Melan-A/MART-1 to a peptide-specific HLA-A*0201+ cytotoxic T cell line. J Immunol. 157:1996;787.
59. Rivoltini L, Loftus D, Barracchini K, Arienti F, Mazzocchi A, Biddison W, Salgaller M, Appella E, Parmiani G, Marincola F. Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. J Immunol. 156:1996;3882.
60. Sidney J, del Guercio MF, Southwood S, Engelhard VH, Appella E, Rammensee HG, Falk K, Rotzschke O, Takiguchi M, Kubo RT, Grey HM, Sette A. Several HLA alleles share overlapping peptide specificities. J Immunol. 154:1995;247.
61. Sidney J, Grey HM, Southwood S, Celis E, Wentworth PA, del Guercio M-F, Kubo RT, Chesnut RW, Sette A. Definition of an HLA-A3 like supermotif demonstrates the overlapping peptide-binding repertoires of common HLA molecules. Human Immunol. 45:1996;79.
62. Bertoni R, Sidney J, Fowler P, Chesnut RW, Chisari FV, Sette A. HLA-binding supermotifs predict broadly crossreactive cytotoxic T lymphocyte responses in patients with acute hepatitis. J Clin Invest. 100:1997;503.
63. Doolan DL, Hoffman SL, Southwood S, Wentworth PA, Sidney J, Chesnut RW, Keogh E, Appella E, Nutman TB, Gordon DM, Oloo A, Lai AA, Sette A. Degenerate cytotoxic T cell epitopes from P falciparim restricted by multiple HLA-A and -B supertype alleles . Immunity. 7:1997;97.
64. van Endert PM, Riganelli D, Greco G, Fleischhauer K, Sidney J, Sette A, Bach J-F. The peptide-binding motif for the human transporter associated with antigen processing. J Exp Med. 182:1995;1883.